The ongoing phase 3 CheckMate-8HW trial has been evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) against Opdivo alone across all lines of therapy, including the front-line, in patients with ...
Citing data from its Phase 3 CheckMate -8HW trial, the pharma giant said that the treatment combo versus Opdivo monotherapy has shown a statistically significant and clinically meaningful ...
Findings from the CheckMate 8HW study were published simultaneously in The Lancet. The phase III trial showed a clear benefit with the combination, achieved with a fairly low rate of AEs ...
日前，百时美施贵宝（Bristol Myers Squibb）宣布3期临床试验CheckMate-8HW的分析结果。该研究评估了Opdivo（纳武利尤单抗）联合Yervoy（伊匹木单抗），对比 ...
CheckMate-8HW此前公布了欧狄沃联合逸沃对比研究者选择的化疗方案的疗效结果，显示欧狄沃联合逸沃可降低79%的疾病进展或死亡风险。该结果已于《新英格兰医学杂志》上发表，欧盟委员会也基于 ...
CheckMate -8HW enrolled patients with colorectal cancer whose tumors were characterized as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback